What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

◆ NeutralIMTX

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

GlobeNewswire Inc.·October 24, 2026

Immatics announced updated clinical trial data for its PRAME-targeting therapies at the 2026 ESMO Annual Meeting. IMA402 bispecific achieved a 32% confirmed objective response rate in PRAME-high melanoma patients with a 12.5-month median duration of response and 91% one-year overall survival rate. IMA203CD8 cell therapy demonstrated a 55% response rate in gynecologic cancers at clinically relevant doses with an 8.4-month median duration of response. Both therapies showed favorable safety profiles, supporting continued development across multiple solid tumor indications.

Read Full Article at GlobeNewswire Inc. →

← Back to Financial Intelligence